BioSpace

FDA will miss rare decision deadline for Savara candidate after three-month delay

Savara shares dropped 18% on the news, though analysts remain confident in approval, instead pointing to potential “bandwidth issues” at the FDA.

By BioSpace

1 min read
FDA will miss rare decision deadline for Savara candidate after three-month delay
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights